Search

Your search keyword '"McShane, Helen"' showing total 903 results
Start Over Author "McShane, Helen"
903 results on '"McShane, Helen"'

2. Challenges in Developing a Controlled Human Tuberculosis Challenge Model

Author

Jackson, Susan, McShane, Helen, Capron, A., Series Editor, Cooper, Max D., Series Editor, Hogle, J.M., Series Editor, Zinkernagel, R., Series Editor, Ito, Y., Series Editor, Koprowski, Hilary, Honorary Editor, McConnell, I., Series Editor, Melchers, Fritz, Series Editor, Oldstone, Michael B. A., Series Editor, Olsnes, Sjur, Series Editor, Potter, Kevin L., Series Editor, Saedler, H., Series Editor, Vogt, Peter K., Series Editor, Wagner, Hermann, Series Editor, Wilson, I., Series Editor, Hofschneider, P.H., Series Editor, Rott, R., Series Editor, Schweiger, H. G, Series Editor, Clarke, A., Series Editor, Eisen, H., Series Editor, Goebel, W., Series Editor, Nussenzweig, V., Series Editor, Doerr, R., Series Editor, Henle, W., Series Editor, Meyer, K. F., Series Editor, Nauck, E.G., Series Editor, Pappenheimer Jr., A. M., Series Editor, Schlossberg, H., Series Editor, Tomcsik, J., Series Editor, Kikuth, W., Series Editor, Arber, W., Series Editor, Virgin, Herbert W., Series Editor, Collier, R. John, Series Editor, Kawaoka, Yoshihiro, Series Editor, Svanborg, Catharina, Series Editor, Gleba, Yuri Y., Series Editor, Ahmed, Rafi, Series Editor, Akira, Shizuo, Series Editor, Aktories, Klaus, Series Editor, Casadevall, Arturo, Series Editor, Compans, Richard W., Series Editor, Damaso, Clarissa, Series Editor, Galan, Jorge E., Series Editor, Garcia-Sastre, Adolfo, Series Editor, Iwasaki, Akiko, Series Editor, Palme, Klaus, Series Editor, Rappuoli, Rino, Series Editor, Honjo, Tasuku, Series Editor, Rodrigues, Marcio L, Series Editor, Weber, Olaf, Series Editor, Bagnoli, Fabio, editor, Del Giudice, Giuseppe, editor, and Phogat, Sanjay K., editor

Published
2024
Full Text
View/download PDF

5. Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial

Author

Satti, Iman, Marshall, Julia L, Harris, Stephanie A, Wittenberg, Rachel, Tanner, Rachel, Lopez Ramon, Raquel, Wilkie, Morven, Ramos Lopez, Fernando, Riste, Michael, Wright, Daniel, Peralta Alvarez, Marco Polo, Williams, Nicola, Morrison, Hazel, Stylianou, Elena, Folegatti, Pedro, Jenkin, Daniel, Vermaak, Samantha, Rask, Linnea, Cabrera Puig, Ingrid, Powell Doherty, Rebecca, Lawrie, Alison, Moss, Paul, Hinks, Timothy, Bettinson, Henry, and McShane, Helen

Published
2024
Full Text
View/download PDF

7. Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study

Author

Alparaque, Maricel, Anid, Liisa, Barnes, Eleanor, Benamore, Rachel, Bharti, Neha, Patel, Bhumika, Burns, Adrian, Byard, Nicholas, Conway, Oliver, Cooper, Cushla, Crowther, Charlotte, Dunachie, Susanna J, Johnstone, Trudi, Jose, Jyolsna, Luciw, Michael, Mujadidi, Yama, Nehiweze, Aiseosa, Nyamunda, Sibongile, Orobiyi-Rieba, Maria, Parvelikudy, Bindu, Platt, Abigail, Pswarayi, Dzikamayi, Quaddy, Jack, Samuel, Binnie Elizabeth, Sette, Alessandro, Sodipo, Victoria, Srijith, Preethu, Stone, Helen, Turner, Cheryl, Valmores, Mary Ann, Voaides, Alexandru, Vuddamalay, Gavindren, Jackson, Susan, Marshall, Julia L, Mawer, Andrew, Lopez-Ramon, Raquel, Harris, Stephanie A, Satti, Iman, Hughes, Eileen, Preston-Jones, Hannah, Cabrera Puig, Ingrid, Longet, Stephanie, Tipton, Tom, Laidlaw, Stephen, Doherty, Rebecca Powell, Morrison, Hazel, Mitchell, Robert, Tanner, Rachel, Ateere, Alberta, Stylianou, Elena, Wu, Meng-San, Fredsgaard-Jones, Timothy P W, Breuer, Judith, Rapeport, Garth, Ferreira, Vanessa M, Gleeson, Fergus, Pollard, Andrew J, Carroll, Miles, Catchpole, Andrew, Chiu, Christopher, and McShane, Helen

Published
2024
Full Text
View/download PDF

11. Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease

Author

Burel, Julie G, Singhania, Akul, Dubelko, Paige, Muller, Julius, Tanner, Rachel, Parizotto, Eneida, Dedicoat, Martin, Fletcher, Thomas E, Dunbar, James, Cunningham, Adam F, Lindestam Arlehamn, Cecilia S, Catanzaro, Donald G, Catanzaro, Antonino, Rodwell, Timothy, McShane, Helen, O'Shea, Matthew K, and Peters, Bjoern

Subjects
Biomedical and Clinical Sciences, Immunology, Tuberculosis, Rare Diseases, Infectious Diseases, Clinical Research, Genetics, Infection, Good Health and Well Being, Adult, Case-Control Studies, England, Female, Gene Expression Profiling, Humans, Latent Tuberculosis, Longitudinal Studies, Male, Middle Aged, Mycobacterium tuberculosis, State Medicine, Tissue Array Analysis, Transcriptome, Latent tuberculosis, Blood transcriptomics, Prophylaxis treatment, Medical and Health Sciences, Microbiology, Clinical sciences, Medical microbiology
Abstract

Although only a small fraction will ever develop the active form of tuberculosis (ATB) disease, chemoprophylaxis treatment in latent TB infected (LTBI) individuals is an effective strategy to control pathogen transmission. Characterizing immune responses in LTBI upon chemoprophylactic treatment is important to facilitate treatment monitoring, and thus improve TB control strategies. Here, we studied changes in the blood transcriptome in a cohort of 42 LTBI and 8 ATB participants who received anti-TB therapy. Based on the expression of previously published gene signatures of progression to ATB, we stratified the LTBI cohort in two groups and examined if individuals deemed to be at elevated risk of developing ATB before treatment (LTBI-Risk) differed from others (LTBI-Other). We found that LTBI-Risk and LTBI-Other groups were associated with two distinct transcriptomic treatment signatures, with the LTBI-Risk signature resembling that of treated ATB patients. Notably, overlapping genes between LTBI-Risk and ATB treatment signatures were associated with risk of progression to ATB and interferon (IFN) signaling, and were selectively downregulated upon treatment in the LTBI-Risk but not the LTBI-Other group. Our results suggest that transcriptomic reprogramming following treatment of LTBI is heterogeneous and can be used to distinguish LTBI-Risk individuals from the LTBI cohort at large.

Published
2021

12. Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial

Author

Namutebi, Milly, Nakazibwe, Esther, Onen, Caroline, Apuule, Barbara, Akello, Florence, Mukasa, Mike, Nnaluwooza, Marble, Sewankambo, Moses, Kiwanuka, Sam, Kiwudhu, Fred, Imede, Esther, Nkurunungi, Gyaviira, Nakawungu, Prossy Kabuubi, Kabami, Grace, Nuwagaba, Emmanuel, Akello, Mirriam, Wajja, Anne, Nassanga, Beatrice, Natukunda, Agnes, Serubanja, Joel, Tumusiime, Josephine, Akurut, Helen, Oduru, Gloria, Nassuuna, Jacent, Kabagenyi, Joyce, Morrison, Hazel, Scott, Hannah, Doherty, Rebecca Powell, Marshall, Julia L, Puig, Ingrid Cabrera, Cose, Stephen, Kaleebu, Pontiano, Webb, Emily L, Satti, Iman, McShane, Helen, and Elliott, Alison M

Published
2024
Full Text
View/download PDF

13. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults

Author

Killingley, Ben, Mann, Alex J., Kalinova, Mariya, Boyers, Alison, Goonawardane, Niluka, Zhou, Jie, Lindsell, Kate, Hare, Samanjit S., Brown, Jonathan, Frise, Rebecca, Smith, Emma, Hopkins, Claire, Noulin, Nicolas, Löndt, Brandon, Wilkinson, Tom, Harden, Stephen, McShane, Helen, Baillet, Mark, Gilbert, Anthony, Jacobs, Michael, Charman, Christine, Mande, Priya, Nguyen-Van-Tam, Jonathan S., Semple, Malcolm G., Read, Robert C., Ferguson, Neil M., Openshaw, Peter J., Rapeport, Garth, Barclay, Wendy S., Catchpole, Andrew P., and Chiu, Christopher

Published
2022
Full Text
View/download PDF

15. A dose escalation study to evaluate the safety of an aerosol BCG infection in previously BCG-vaccinated healthy human UK adults.

Author

Fredsgaard-Jones, Timothy, Harris, Stephanie A., Morrison, Hazel, Ateere, Alberta, Nassanga, Beatrice, Ramon, Raquel Lopez, Mitton, Celia, Fletcher, Eve, Decker, Jonathan, Preston-Jones, Hannah, Jackson, Susan, Mawer, Andrew, Satti, Iman, Barer, Michael, Hinks, Timothy, Bettinson, Henry, and McShane, Helen

Subjects
PULMONARY function tests, TUBERCULOSIS vaccines, MYCOBACTERIUM tuberculosis, BRONCHOALVEOLAR lavage, VACCINE development
Abstract

Introduction: Tuberculosis (TB) is the leading cause of death worldwide from a single infectious agent. Bacillus Calmette-Guérin (BCG), the only licensed vaccine, provides limited protection. Controlled human infection models (CHIMs) are useful in accelerating vaccine development for pathogens with no correlates of protection; however, the need for prolonged treatment makes Mycobacterium tuberculosis an unethical challenge agent. Aerosolised BCG provides a potential safe surrogate of infection. A CHIM in BCG-vaccinated as well as BCG-naïve individuals would allow identification of novel BCG-booster vaccine candidates and facilitate CHIM studies in populations with high TB endemicity. The purpose of this study was to evaluate the safety and utility of an aerosol BCG CHIM in historically BCG-vaccinated volunteers. Methods: There were 12 healthy, historically BCG-vaccinated UK adults sequentially enrolled into dose-escalating groups. The first three received 1 × 104 CFU aerosol BCG Danish 1331 via a nebuliser. After safety review, subsequent groups received doses of 1 × 105 CFU, 1 × 106 CFU, or 1 × 107 CFU. Safety was monitored through self-reported adverse events (AEs), laboratory tests, and lung function testing. Immunology blood samples were taken pre-infection and at multiple timepoints post-infection. A bronchoalveolar lavage (BAL) taken 14 days post-infection was analysed for presence of live BCG. Results: No serious AEs occurred during the study. Solicited systemic and respiratory AEs were frequent in all groups, but generally short-lived and mild in severity. There was a trend for more reported AEs in the highest-dose group. No live BCG was detected in BAL from any volunteers. Aerosol BCG induced potent systemic cellular immune responses in the highest-dose group 7 days post-infection. Discussion: Aerosol BCG infection up to a dose of 1 × 107 CFU was well-tolerated in historically BCG-vaccinated healthy, UK adults. No live BCG was detected in the BAL fluid 14 days post-infection despite potent systemic responses, suggesting early clearance. Further work is needed to expand the number of volunteers receiving BCG via the aerosol route to refine and establish utility of this aerosol BCG CHIM. Clinical trial registration: https://clinicaltrials.gov/ , identifier NCT04777721. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Mtb -Specific HLA-E-Restricted T Cells Are Induced during Mtb Infection but Not after BCG Administration in Non-Human Primates and Humans.

Author

Voogd, Linda, van Wolfswinkel, Marjolein, Satti, Iman, White, Andrew D., Dijkman, Karin, Gela, Anele, van Meijgaarden, Krista E., Franken, Kees L. M. C., Marshall, Julia L., Ottenhoff, Tom H. M., Scriba, Thomas J., McShane, Helen, Sharpe, Sally A., Verreck, Frank A. W., and Joosten, Simone A.

Subjects
T cells, BCG vaccines, TUBERCULOSIS vaccines, MYCOBACTERIUM tuberculosis, RHESUS monkeys
Abstract

Background: Novel vaccines targeting the world's deadliest pathogen Mycobacterium tuberculosis (Mtb) are urgently needed as the efficacy of the Bacillus Calmette–Guérin (BCG) vaccine in its current use is limited. HLA-E is a virtually monomorphic unconventional antigen presentation molecule, and HLA-E-restricted Mtb-specific CD8+ T cells can control intracellular Mtb growth, making HLA-E a promising vaccine target for Mtb. Methods: In this study, we evaluated the frequency and phenotype of HLA-E-restricted Mtb-specific CD4+/CD8+ T cells in the circulation and bronchoalveolar lavage fluid of two independent non-human primate (NHP) studies and from humans receiving BCG either intradermally or mucosally. Results: BCG vaccination followed by Mtb challenge in NHPs did not affect the frequency of circulating and local HLA-E–Mtb CD4+ and CD8+ T cells, and we saw the same in humans receiving BCG. HLA-E–Mtb T cell frequencies were significantly increased after Mtb challenge in unvaccinated NHPs, which was correlated with higher TB pathology. Conclusions: Together, HLA-E–Mtb-restricted T cells are minimally induced by BCG in humans and rhesus macaques (RMs) but can be elicited after Mtb infection in unvaccinated RMs. These results give new insights into targeting HLA-E as a potential immune mechanism against TB. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Tuberculosis Vaccines

Author

Morrison, Hazel, Tait, Dereck R., McShane, Helen, Ginsberg, Ann M., Migliori, Giovanni Battista, editor, and Raviglione, Mario C., editor

Published
2021
Full Text
View/download PDF

18. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Author

Williams, Bryan, Turner, Rebecca, Libri, Vincenzo, Mussai, Francis, Middleton, Gary, Bowden, Sarah, Bangash, Mansoor, Gao-Smith, Fang, Patel, Jaimin, Sapey, Elizabeth, Thomas, Mark, Coles, Mark, Watkinson, Peter, Rahman, Naj, Angus, Brian, Mentzer, Alexander J., Novak, Alex, Feldman, Marc, Richter, Alex, Faustini, Sian, Bathurst, Camilla, Van de Wiel, Joseph, Mee, Susie, James, Karen, Rahman, Bushra, Turner, Karen, Hill, Adam, Gordon, Anthony, Yap, Christina, Matthay, Michael, McAuley, Danny, Hall, Andrew, Dark, Paul, McMichael, Andrew, Fisher, Benjamin A, Veenith, Tonny, Slade, Daniel, Gaskell, Charlotte, Rowland, Matthew, Whitehouse, Tony, Scriven, James, Parekh, Dhruv, Balasubramaniam, Madhu S, Cooke, Graham, Morley, Nick, Gabriel, Zoe, Wise, Matthew P, Porter, Joanna, McShane, Helen, Ho, Ling-Pei, Newsome, Philip N, Rowe, Anna, Sharpe, Rowena, Thickett, David R, Bion, Julian, Gates, Simon, Richards, Duncan, and Kearns, Pamela

Published
2022
Full Text
View/download PDF

22. Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates

Author

Peralta Alvarez, Marco Polo, primary, Jones, Holly, additional, Redondo Azema, Hugo, additional, Davis, Chloe, additional, White, Andrew D., additional, Sarfas, Charlotte, additional, Dennis, Mike, additional, Li, Shuailin, additional, Wright, Daniel, additional, Puentes, Eugenia, additional, Kimuda, Simon, additional, Belij-Rammerstorfer, Sandra, additional, Aguilo, Nacho, additional, Martin, Carlos, additional, Sharpe, Sally, additional, McShane, Helen, additional, and Tanner, Rachel, additional

Published
2024
Full Text
View/download PDF

23. Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease

Author

Burel, Julie G., Singhania, Akul, Dubelko, Paige, Muller, Julius, Tanner, Rachel, Parizotto, Eneida, Dedicoat, Martin, Fletcher, Thomas E., Dunbar, James, Cunningham, Adam F., Lindestam Arlehamn, Cecilia S., Catanzaro, Donald G., Catanzaro, Antonino, Rodwell, Timothy, McShane, Helen, O'Shea, Matthew K., and Peters, Bjoern

Published
2021
Full Text
View/download PDF

25. Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial

Author

Freeman, Daniel, Loe, Bao Sheng, Yu, Ly-Mee, Freeman, Jason, Chadwick, Andrew, Vaccari, Cristian, Shanyinde, Milensu, Harris, Victoria, Waite, Felicity, Rosebrock, Laina, Petit, Ariane, Vanderslott, Samantha, Lewandowsky, Stephan, Larkin, Michael, Innocenti, Stefania, Pollard, Andrew J, McShane, Helen, and Lambe, Sinéad

Published
2021
Full Text
View/download PDF

26. Review of Current Tuberculosis Human Infection Studies for Use in Accelerating Tuberculosis Vaccine Development: A Meeting Report.

Author

Balasingam, Shobana, Dheda, Keertan, Fortune, Sarah, Gordon, Stephen B, Hoft, Daniel, Kublin, James G, Loynachan, Colleen N, McShane, Helen, Morton, Ben, Nambiar, Sujatha, Sharma, Nimisha Raj, Robertson, Brian, Schrager, Lewis K, and Weller, Charlotte L

Subjects
VACCINE development, TUBERCULOSIS vaccines, BCG vaccines, AIDS vaccines, DRUG development
Abstract

Tools to evaluate and accelerate tuberculosis (TB) vaccine development are needed to advance global TB control strategies. Validated human infection studies for TB have the potential to facilitate breakthroughs in understanding disease pathogenesis, identify correlates of protection, develop diagnostic tools, and accelerate and de-risk vaccine and drug development. However, key challenges remain for realizing the clinical utility of these models, which require further discussion and alignment among key stakeholders. In March 2023, the Wellcome Trust and the International AIDS Vaccine Initiative convened international experts involved in developing both TB and bacillus Calmette-Guérin (BCG) human infection studies (including mucosal and intradermal challenge routes) to discuss the status of each of the models and the key enablers to move the field forward. This report provides a summary of the presentations and discussion from the meeting. Discussions identified key issues, including demonstrating model validity, to provide confidence for vaccine developers, which may be addressed through demonstration of known vaccine effects (eg, BCG vaccination in specific populations), and by comparing results from field efficacy and human infection studies. The workshop underscored the importance of establishing safe and acceptable studies in high-burden settings, and the need to validate >1 model to allow for different scientific questions to be addressed as well as to provide confidence to vaccine developers and regulators around use of human infection study data in vaccine development and licensure pathways. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS‐CoV‐2.

Author

Higham, Helen E., Morgan, Lauren, Cooper, Cushla, Marshall, Julia, Mawer, Andrew, Jackson, Susan, Lopez‐Ramon, Raquel, Hughes, Eileen, Richards, Duncan, McShane, Helen, and Fullerton, James N.

Subjects
EXPERIMENTAL medicine, SARS-CoV-2, INFECTION control, PILOT projects, SAFETY factor in engineering
Abstract

Aims: The influence of human factors on safety in healthcare settings is well established, with targeted interventions reducing risk and enhancing team performance. In experimental and early phase clinical research participant safety is paramount and safeguarded by guidelines, protocolized care and staff training; however, the real‐world interaction and implementation of these risk‐mitigating measures has never been subjected to formal system‐based assessment. Methods: Independent structured observations, systematic review of study documents, and interviews and focus groups were used to collate data on three key tasks undertaken in a clinical research facility (CRF) during a SARS CoV‐2 controlled human infection model (CHIM) study. The Systems Engineering Initiative for Patient Safety (SEIPS) was employed to analyse and categorize findings, and develop recommendations for safety interventions. Results: High levels of team functioning and a clear focus on participant safety were evident throughout the study. Despite this, latent risks in both study‐specific and CRF work systems were identified in all four SEIPS domains (people, environment, tasks and tools). Fourteen actionable recommendations were generated collaboratively. These included inter‐organization and inter‐study standardization, optimized checklists for safety critical tasks, and use of simulation for team training and exploration of work systems. Conclusions: This pioneering application of human factors techniques to analyse work systems during the conduct of research in a CRF revealed risks unidentified by routine review and appraisal, and despite international guideline adherence. SEIPS may aid categorization of system problems and the formulation of recommendations that reduce risk and mitigate potential harm applicable across a trials portfolio. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Third human challenge trial conference, Oxford, United Kingdom, February 6–7, 2020, a meeting report

Author

Balasingam, Shobana, Bejon, Philippe, Berthels, Nele, Bull, Susan, Catchpole, Andrew, Chi, Primus, Chilengi, Roma, Cox, Rebecca, Davies, Hugh, Durbin, Anna, Emary, Kate, Emerson, Claudia, Frenck, Robert, Grimwade, Olivia, Hobbs, Marcia, Kang, Gagandeep, Kaye, Paul, Le Doare, Kirsty, Levine, Mike, McShane, Helen, Oguti, Blanche, Openshaw, Peter, Osowicki, Joshua, Parker, Michael, Ploin, Dominique, Porter, Chad, Roestenberg, Meta, Selgelid, Michael J., Wildfire, Adrian, Pollard, Andrew J., Sauerwein, Robert, Baay, Marc, and Neels, Pieter

Published
2020
Full Text
View/download PDF

29. Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial

Author

Wajja, Anne, primary, Nassanga, Beatrice, additional, Natukunda, Agnes, additional, Serubanja, Joel, additional, Tumusiime, Josephine, additional, Akurut, Helen, additional, Oduru, Gloria, additional, Nassuuna, Jacent, additional, Kabagenyi, Joyce, additional, Morrison, Hazel, additional, Scott, Hannah, additional, Doherty, Rebecca Powell, additional, Marshall, Julia L, additional, Puig, Ingrid Cabrera, additional, Cose, Stephen, additional, Kaleebu, Pontiano, additional, Webb, Emily L, additional, Satti, Iman, additional, McShane, Helen, additional, Elliott, Alison M, additional, Namutebi, Milly, additional, Nakazibwe, Esther, additional, Onen, Caroline, additional, Apuule, Barbara, additional, Akello, Florence, additional, Mukasa, Mike, additional, Nnaluwooza, Marble, additional, Sewankambo, Moses, additional, Kiwanuka, Sam, additional, Kiwudhu, Fred, additional, Imede, Esther, additional, Nkurunungi, Gyaviira, additional, Nakawungu, Prossy Kabuubi, additional, Kabami, Grace, additional, Nuwagaba, Emmanuel, additional, and Akello, Mirriam, additional

Published
2024
Full Text
View/download PDF

30. Deficiency of factor-inhibiting HIF creates a tumor-promoting immune microenvironment

Author

Ma, Jingyi, primary, Al Moussawi, Khatoun, additional, Lou, Hantao, additional, Chan, Hok Fung, additional, Wang, Yihua, additional, Chadwick, Joseph, additional, Phetsouphanh, Chansavath, additional, Slee, Elizabeth A., additional, Zhong, Shan, additional, Leissing, Thomas M., additional, Roth, Andrew, additional, Qin, Xiao, additional, Chen, Shuo, additional, Yin, Jie, additional, Ratnayaka, Indrika, additional, Hu, Yang, additional, Louphrasitthiphol, Pakavarin, additional, Taylor, Lewis, additional, Bettencourt, Paulo J. G., additional, Muers, Mary, additional, Greaves, David R., additional, McShane, Helen, additional, Goldin, Robert, additional, Soilleux, Elizabeth J., additional, Coleman, Mathew L., additional, Ratcliffe, Peter J., additional, and Lu, Xin, additional

Published
2024
Full Text
View/download PDF

32. Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control

Author

Wajja, Anne, primary, Nassanga, Beatrice, additional, Natukunda, Agnes, additional, Serubanja, Joel, additional, Tumusiime, Josephine, additional, Akurut, Helen, additional, Oduru, Gloria, additional, Nassuuna, Jacent, additional, Kabagenyi, Joyce, additional, Morrison, Hazel, additional, Scott, Hannah, additional, Powell Doherty, Rebecca, additional, Marshall, Julia L, additional, Cabrera Puig, Ingrid, additional, Cose, Stephen, additional, Kaleebu, Pontiano, additional, Webb, Emily L, additional, Satti, Iman, additional, McShane, Helen, additional, and Elliott, Alison M, additional

Published
2024
Full Text
View/download PDF

34. High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation

Author

Sibley, Laura, White, Andrew D., Gooch, Karen E., Stevens, Lisa M., Tanner, Rachel, Jacobs, Ashley, Daykin-Pont, Owen, Gleeson, Fergus, McIntyre, Anthony, Basaraba, Randall, Clark, Simon, Hall, Graham, Pearson, Geoff, Rayner, Emma, McShane, Helen, Williams, Ann, Dennis, Mike, Marsh, Philip D., and Sharpe, Sally

Published
2021
Full Text
View/download PDF

43. Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers : A Phase 2 Randomized, Controlled Trial

Author

MVA029 Study Team, Nemes, Elisa, Hesseling, Anneke C., Tameris, Michele, Mauff, Katya, Downing, Katrina, Mulenga, Humphrey, Rose, Penelope, van der Zalm, Marieke, Mbaba, Sharon, Van As, Danelle, Hanekom, Willem A., Walzl, Gerhard, Scriba, Thomas J., McShane, Helen, and Hatherill, Mark

Published
2018

46. Healthy volunteer symptom profile following research bronchoscopy

Author

Morrison, Hazel, primary, Jackson, Susan, additional, Marshall, Julia, additional, Mitton, Celia, additional, Lopez Ramon, Raquel, additional, Fredsgaard-Jones, Timothy, additional, Mawer, Andrew, additional, Wilkins, Clare, additional, Bettinson, Henry, additional, Hinks, Timothy, additional, and Mcshane, Helen, additional

Published
2023
Full Text
View/download PDF

48. Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2

Author

Higham, Helen, primary, Morgan, Lauren, additional, Cooper, Cushla, additional, Marshall, Julia, additional, Mawer, Andrew, additional, Jackson, Susan, additional, Lopez-Ramon, Raquel, additional, Hughes, Eileen, additional, Richards, Duncan, additional, McShane, Helen, additional, and Fullerton, James, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results